AMAG Pharmaceuticals (AMAG) Sees Strong Trading Volume

AMAG Pharmaceuticals, Inc. (NASDAQ:AMAG) shares saw strong trading volume on Friday . 11,653,000 shares were traded during mid-day trading, an increase of 764% from the previous session’s volume of 1,348,290 shares.The stock last traded at $17.95 and had previously closed at $17.95.

A number of equities research analysts have commented on the company. Jefferies Group reissued a “buy” rating and issued a $16.00 price objective on shares of AMAG Pharmaceuticals in a research note on Sunday, November 5th. ValuEngine cut AMAG Pharmaceuticals from a “hold” rating to a “sell” rating in a research note on Friday, February 2nd. Cantor Fitzgerald reissued a “hold” rating and issued a $17.00 price objective on shares of AMAG Pharmaceuticals in a research note on Wednesday. Piper Jaffray Companies assumed coverage on AMAG Pharmaceuticals in a research note on Monday, October 23rd. They issued a “neutral” rating and a $18.00 price objective for the company. Finally, B. Riley reissued a “hold” rating and issued a $16.00 price objective on shares of AMAG Pharmaceuticals in a research note on Monday, January 29th. One research analyst has rated the stock with a sell rating, ten have issued a hold rating and three have assigned a buy rating to the company’s stock. AMAG Pharmaceuticals currently has a consensus rating of “Hold” and a consensus price target of $21.82.

The company has a market cap of $672.84, a PE ratio of -3.04 and a beta of 0.79. The company has a debt-to-equity ratio of 0.94, a quick ratio of 1.48 and a current ratio of 1.59.

Several large investors have recently made changes to their positions in AMAG. Bogle Investment Management L P DE purchased a new position in shares of AMAG Pharmaceuticals during the fourth quarter valued at approximately $4,352,000. State Street Corp boosted its position in shares of AMAG Pharmaceuticals by 10.6% during the second quarter. State Street Corp now owns 2,789,932 shares of the specialty pharmaceutical company’s stock valued at $51,336,000 after buying an additional 267,873 shares during the last quarter. Tocqueville Asset Management L.P. purchased a new position in shares of AMAG Pharmaceuticals during the third quarter valued at approximately $3,958,000. Prudential Financial Inc. boosted its position in shares of AMAG Pharmaceuticals by 35.7% during the third quarter. Prudential Financial Inc. now owns 725,357 shares of the specialty pharmaceutical company’s stock valued at $13,382,000 after buying an additional 190,660 shares during the last quarter. Finally, Dimensional Fund Advisors LP boosted its position in shares of AMAG Pharmaceuticals by 18.5% during the second quarter. Dimensional Fund Advisors LP now owns 1,215,249 shares of the specialty pharmaceutical company’s stock valued at $22,361,000 after buying an additional 189,576 shares during the last quarter.

ILLEGAL ACTIVITY WARNING: This article was first published by StockNewsTimes and is the sole property of of StockNewsTimes. If you are viewing this article on another site, it was illegally copied and reposted in violation of U.S. & international copyright & trademark laws. The original version of this article can be viewed at https://stocknewstimes.com/2018/02/18/amag-pharmaceuticals-amag-sees-strong-trading-volume.html.

AMAG Pharmaceuticals Company Profile

AMAG Pharmaceuticals, Inc is a pharmaceutical company. The Company’s segment is the manufacture, development and commercialization of products and services for use in treating various conditions, with a focus on maternal health, anemia management and cancer supportive care. Its offerings focus on maternal health, anemia management and cancer supportive care, including its product, Makena (hydroxyprogesterone caproate injection); services related to the collection, processing and storage of umbilical cord blood stem cell and cord tissue units operated through Cord Blood Registry (CBR); its product, Feraheme (ferumoxytol), for intravenous (IV) use, and MuGard Mucoadhesive Oral Wound Rinse.

Receive News & Ratings for AMAG Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for AMAG Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.

Latest News

Leave a Reply